CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
about
Purinergic signalling and cancerThe anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cellsA₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.Pharmacological and therapeutic effects of A3 adenosine receptor agonistsControlling murine and rat chronic pain through A3 adenosine receptor activationCF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.Investigational A₃ adenosine receptor targeting agents.Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles.Immunomodulation using agonists and antagonists: potential clinical applications.Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism.A binding kinetics study of human adenosine A3 receptor agonists.Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic PoN6-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A3 Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation.
P2860
Q24618782-153A6605-4165-43FF-B5B5-971BBEED82E2Q28728011-E660912C-E587-4B7E-B6BB-5439AB863B9AQ34412639-A9047AFC-905A-4758-A0E1-E71901350FB8Q34680354-31A09D22-4A93-4B46-AFA8-E6DDA78BBDC4Q35560040-0FBD444C-F2FA-4117-88A4-DEE8E2983DC0Q35788500-4F0269D1-7785-4F38-A64E-043E591EF41DQ35913037-FC501E12-B64B-4D75-8681-E05418C39C49Q36565624-DEA09E54-A053-4350-BFE0-0C951BF8B560Q36731575-92DFC6A6-1F0F-48A1-A9C2-CDF9B003DDBBQ36821548-34145A09-E3AF-474D-8A98-544A41EA1AECQ37965728-384210F5-7165-41A6-B185-F3D4A78E7E24Q38136285-B0CC209E-BB69-4274-AC85-E86D91BE03EEQ39148961-435E2EDD-268F-4C2F-9592-A5530BAB75D5Q39418010-85D71FB2-CC81-4A61-9FB2-37460683A9ADQ42950461-D5350BC2-5551-45EF-9069-DE2362578F24Q47804733-73A5B4C7-1906-47D5-AF9B-F136E6616A72Q47964767-EE54A951-5BC8-43B2-8499-9EDB9CB6FD53Q48316436-AC1AB13E-1ADC-4D14-BF6D-CB1F7264E8FB
P2860
CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@ast
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@en
type
label
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@ast
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@en
prefLabel
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@ast
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@en
P2093
P2860
P356
P1476
CF102 an A3 adenosine receptor ...... ammatory effects in the liver.
@en
P2093
K A Jacobson
L Rath-Wolfson
S Bar-Yehuda
S M Stemmer
P2860
P304
P356
10.1002/JCP.22593
P577
2011-09-01T00:00:00Z